Crizotinib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3822 publications
ALK -Rearranged Renal Cell Carcinoma : Morphologic Spectrum and Genomic Landscape From a Multi-Institutional Cohort of 16 Cases.
Journal: The American journal of surgical pathology
Published: March 06, 2026
Gastrointestinal pH Gradient-Induced Phase Transition of Crizotinib: The Significance of pH-Dependent Ionization (Protonation) on Liquid-Liquid Phase Separation of a Weakly Basic Drug.
Journal: Molecular pharmaceutics
Published: March 05, 2026
Enhanced Efficacy and Safety of 177Lu-Anti-CD25 Radioimmunotherapy by Combination with Targeted Anticancer Agents.
Journal: Molecular pharmaceutics
Published: March 03, 2026
Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation.
Journal: Pharmaceutical medicine
Published: March 02, 2026
Inhibition of Four Anaplastic Lymphoma Kinase Inhibitors on the Activity of Human UDP-Glucuronosyltransferases and Prediction of Drug-Drug Interactions.
Journal: Chemical research in toxicology
Published: February 27, 2026
Intracranial efficacy of systemic therapies for patients with ALK-positive non-small cell lung cancer in patients with brain metastases: a systematic review and meta-analysis.
Journal: Journal of chemotherapy (Florence, Italy)
Published: February 23, 2026
The association between anti-acid use and tyrosine kinase inhibitor-induced hepatotoxicity.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: February 16, 2026
Case report: successful use of repotrectinib in a ROS1 fusion-positive lung adenocarcinoma patient with severe renal insufficiency and prior tyrosine kinase inhibitor treatment failure.
Journal: Anti-cancer drugs
Published: February 11, 2026
Proteomic insights into Helicobacter pylori infection in stomach cells, revealing host response and host-targeted therapeutics repurposing.
Journal: Expert review of proteomics
Published: February 10, 2026
Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration.
Journal: British journal of haematology
Published: February 06, 2026
Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China.
Journal: Lung cancer management
Published: February 03, 2026
Last Updated: 04/28/2026